Children's Health: Smoke from forest fires aggravates respiratory health of children.♦ New drugs could stop growth of drug-resistant childhood tumors

Researchers document self-reported use of new, uncommon synthetic drugs by teens, young adults This is the first study reporting on use of a variety of new drugs in a nationally representative U.S. sample. Researchers are confident that use was severely underreported, as the subjects were not asked about most of these new drugs specifically. The researchers advocate for health surveys to ask about use of new drugs, in addition to traditional drugs such as marijuana and cocaine, in order to quickly pick up on potential drug epidemics.

New drugs could stop growth of drug-resistant childhood tumors New drugs are needed to treat the most common type of childhood brain tumor and could also be effective against skin cancer, scientists report. They tested a drug called Roflumilast in mice with a brain tumor that is resistant to Vismodegib, the drug in current use. Roflumilast is normally used to treat inflammatory lung diseases. It dramatically inhibited tumor growth from the first day of treatment.

Smoke from forest fires aggravates respiratory health of children. Air pollution from forest fires aggravates the respiratory health of children.Researchers conclude that this study provides scientific evidence that wildfires, such as those that devastated a large part of the province of Valencia, Spain in 2012, affect the health of children, especially of those who are more susceptible.

Video game warnings fall far short in rating tobacco content Video games are not adequately rated for tobacco content video gamers are being widely exposed to tobacco imagery

Solo grandparents raising grandchildren at greater risk than parents for serious health problems Single grandparents raising grandchildren are more vulnerable to poor physical and mental health than are single parents. These caregivers may be at greater risk for diminished physical capacity and heightened prevalence of depression.

Potential Vaccine against early Childhood Pneumonia and Bronchiolitis

An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.

Early-stage human clinical trials of the candidate vaccine are planned. The scientist built on their previous findings about the structure of a critical viral protein to design the vaccine. The team was led by Peter D. Kwong, Ph.D., and Barney S. Graham, M.D., Ph.D.

The respiratory syncytial virus (RSV) is responsible for a common chidhood illness. There is no vaccine available to prevent RSV infection.

In the United States, RSV infection is the most common cause of bronchiolitis (inflammation of small airways in the lungs) and pneumonia in children less than one year old and the most common cause for hospitalization in children under five. Worldwide, it is estimated that RSV is responsible for nearly 7 percent of deaths in babies aged 1 month to 1 year; only malaria kills more children in this age group. Others at risk for severe disease following RSV infection include adults over age 65 and those with compromised immune systems.

“Many common diseases of childhood are now vaccine-preventable, but a vaccine against RSV infection has eluded us for decades,” said NIAID Director Anthony S. Fauci, M.D. “This work marks a major step forward. Not only does the experimental vaccine developed by our scientists elicit strong RSV-neutralizing activity in animals, but, more broadly, this technique of using structural information to inform vaccine design is being applied to other viral diseases, including HIV/AIDS.”

Viruses are made of proteins.For a vaccine to work there need to be a protein that is the same shape as the virus but will not cause illness. When The immune system comes in contact with the vaccine it learns to attack this protein. That way your immune system will attack the virus when it comes in concact with them.

“Here is a case in which information gained from structural biology has provided the insight needed to solve an immunological puzzle and apply the findings to address a real-world public health problem,” said Dr. Graham. He and the VRC scientists are continuing to refine the engineered F glycoproteins and hope to launch early-stage human clinical trials of a candidate RSV vaccine as soon as clinical grade material can be manufactured, a process that takes about 18 to 24 months.

“Previously, structure-based vaccine design held promise at a conceptual level,” said Dr. Kwong. “This advance delivers on that promise and sets the stage for similar applications of structure-guided design to effective vaccines against other pathogens.”

Dr. Fauci added, “This latest advance underscores the advantages of the VRC’s organizational design, where experts in RSV virology, vaccinology and clinical studies, such as Dr. Graham, are in daily contact with Dr. Kwong and others who are experts in structural biology. Such close collaboration across disciplines allows for rapid testing of new approaches to a given problem.”

Source NIH